Memo Therapeutics refuels with $22M to expand trial for infection-fighting antibody in kidney transplant recipients

Swiss biotech Memo Therapeutics raised $22 million (CHF 20 million) in a Series C extension to develop an antibody treatment for BK polyomavirus (BKV) infection in kidney transplant recipients, a condition that currently doesn’t have any approved treatments.

Last year, Memo raised about $27.6 million (CHF 25 million) in a Series C financing round, bringing the total raised for the company to $49.6 million (CHF 45 million). Ysios Capital and Kurma Partners participated in the extension round, joining existing investors that included Pureos Bioventures and Swisscanto, among others.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。